Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
161.92
-3.30 (-2.00%)
5:16:58 PM EDT: $161.70 -0.22 (-0.14%)
Products

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted For Teclistamab For The Treatment Of Relapsed Or Refractory Multiple Myeloma

Published: 06/01/2021 13:04 GMT
Johnson & Johnson (JNJ) - Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed Or Refractory Multiple Myeloma.
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed Or Refractory Multiple Myeloma.